Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L A Zwelling

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Toxicology Letters|April 1, 1993
Consequences of the resistance to drug-induced topoisomerase II-mediated DNA cleavageL A Zwelling
Hematologic Pathology|January 1, 1989
Topoisomerase II as a target of antileukemia drugs: a review of controversial areasL A Zwelling
Cancer Metastasis Reviews|January 1, 1985
DNA topoisomerase II as a target of antineoplastic drug therapyL A Zwelling
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Cisplatin and new platinum analogsL A Zwelling
Molecular Endocrinology (Baltimore, Md.)|April 1, 1988
Receptors and topoisomerase one protein, two functions, not alwaysL A Zwelling
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Cisplatin and new platinum analogsL A Zwelling
Academic Medicine : Journal of the Association of American Medical Colleges|November 1, 1996
Importance and difficulty of determining the cost of clinical researchD Stedman, L A Zwelling
Biochemical and Biophysical Research Communications|March 27, 1997
Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoterC E Herzog, L A Zwelling
Mutation Research|May 1, 1982
DNA-repair deficiencies do not affect intercalator-induced cytotoxicity or DNA scission in human cellsL A Zwelling, M R Mattern
JAMA|April 20, 2001
Protecting the privacy of family members in researchC A Brunelli, L A Zwelling
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Toxicology Letters|April 1, 1993
Consequences of the resistance to drug-induced topoisomerase II-mediated DNA cleavageL A Zwelling
Hematologic Pathology|January 1, 1989
Topoisomerase II as a target of antileukemia drugs: a review of controversial areasL A Zwelling
Cancer Metastasis Reviews|January 1, 1985
DNA topoisomerase II as a target of antineoplastic drug therapyL A Zwelling
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Cisplatin and new platinum analogsL A Zwelling
Molecular Endocrinology (Baltimore, Md.)|April 1, 1988
Receptors and topoisomerase one protein, two functions, not alwaysL A Zwelling
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Cisplatin and new platinum analogsL A Zwelling
Academic Medicine : Journal of the Association of American Medical Colleges|November 1, 1996
Importance and difficulty of determining the cost of clinical researchD Stedman, L A Zwelling
Biochemical and Biophysical Research Communications|March 27, 1997
Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoterC E Herzog, L A Zwelling
Mutation Research|May 1, 1982
DNA-repair deficiencies do not affect intercalator-induced cytotoxicity or DNA scission in human cellsL A Zwelling, M R Mattern
JAMA|April 20, 2001
Protecting the privacy of family members in researchC A Brunelli, L A Zwelling
Pageof 12